Figure 6
From: E2F4 regulatory program predicts patient survival prognosis in breast cancer
E2F4 scores in different molecular subtypes of breast cancer. (A) The survival curves of patients in five molecular subtypes. (B) The number of samples with positive (red) and negative (green) E2F4 iRASs in each molecular subtype. For the subtypes with relatively good prognosis, luminal A and normal-like, there is a high fraction of positive E2F4 iRAS samples, while the subtypes with relatively poor prognosis, HER2-enriched, luminal B and basal-like, have predominantly high fractions of negative E2F4 iRAS samples (A) compared to (B). iRASs, individual regulatory activity scores.